Company / Return on Assets (ROA)
Fulcrum Therapeutics, Inc. Return on Assets (ROA) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-20.4%
FY2025
5-year range
-48.5% / -3.7%
FY2021-FY2025
Trend
-448.0%
vs FY2024
Sector context
#102 of 213
Health Care
What the data says
Return on Assets (ROA) changed -448% YoY in FY2025, a notable deviation from the 7-year average annual change of -59%.
Based on SEC 10-K filings.
-20.4% in FY2025 with a 5-year CAGR of +34.2%.
Improved from -37.8% to -20.4% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +28.0pp
- 5-Year Change
- +34.2pp
- 10-Year Change
- -
Sector benchmark
#102 of 213 in Health CareTop 48% of 213This company -20.4% Sector average -24.1%
▼
+15.3% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 448.0% year-over-year.
- Currently 3.7pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2024.
- Lowest return on assets (roa) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -20.4% | -448.0% |
| FY2024 | -3.7% | +90.1% |
| FY2023 | -37.8% | +22.1% |
| FY2022 | -48.5% | -40.9% |
| FY2021 | -34.4% | +37.1% |
| FY2020 | -54.6% | +27.0% |
| FY2019 | -74.9% | -97.1% |
| FY2018 | -38.0% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026